PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...

Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.

A summary of current health news, including a Nipah virus death in Kerala, an mpox case rise in Uganda, and Pfizer's efforts ...

Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC: New York Monday, September 16, 2024, 10:00 Hrs [IST ...

Pfizer (NYSE: PFE) released longer-term follow-up results from the Phase II single-arm PHAROS clinical trial evaluating the efficacy and safety of Braftovi (encorafenib) in combination with Mektovi ...

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

This roundup covers various health news highlights including the mpox outbreak in Africa and vaccine distribution issues, the ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) is redefining patient engagement and care through its pioneering Experience Ambassadors Program. This initiative empowers selected employees ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...

Mox Capital, a trailblazer in alternative investments with AUM of US$1.4 billion, is announcing its strategic support for a vast array and variety of regional high-potential startups. According to COO ...